Clearmind Medicine Advances Alcohol Use Disorder Trial

Introduction

Clearmind Medicine Inc (NASDAQ: CMND; CSE: CWY0) is a clinical-stage biotechnology company headquartered in Vancouver, British Columbia. The company focuses on developing novel psychedelic-derived therapeutics targeting binge behaviour and mental health disorders, including alcohol use disorder (AUD), binge eating, and depression. Its lead molecule, 5-Methoxy-2-aminoindane (MEAI), is being investigated as an oral treatment to reduce alcohol cravings and consumption.

Corporate Structure and Leadership

Founded in 2021, Clearmind Medicine maintains a team of 11–50 employees and operates with an organizational structure designed for clinical development. The company’s management includes Dr. Adi Zuloff-Shani, a Biomedical Research and Development Executive with over 20 years of experience in regulated healthcare environments. Clearmind holds intellectual property protection around its MEAI-based drug candidates and has established partnerships with academic and clinical sites in North America, Europe, and Israel.

Psychedelic therapy by Alexander Grey

Recent Developments and News

On June 5, 2025, Clearmind announced the enrollment of the first participant in its Phase I/IIa clinical trial (CMND-100) at Yale School of Medicine’s Department of Psychiatry. The trial will evaluate safety, tolerability, and pharmacokinetics, with preliminary assessments of efficacy in reducing alcohol use.

Subsequent filings with the U.S. Securities and Exchange Commission documented further trial expansions:

• June 23, 2025: Addition of a leading Israeli clinical site to the CMND-100 study.
• June 27, 2025: Expansion of global enrolment efforts for the AUD trial, highlighting regulatory and operational steps to increase patient recruitment.
• June 30, 2025: Formal notice of the first dosing milestone filed in SEC Form 6-K, marking a step toward proof-of-concept data.

On July 1, 2025, the company extended holiday wishes to its stakeholders and reiterated its commitment to advancing MEAI as a treatment option.

Financial and Strategic Analysis

As of July 3, 2025, CMND shares closed at USD 1.32, reflecting a 46.18% increase from the prior close, on a total volume of 4,579,238 shares trading on the NASDAQ. Key financial metrics from the trailing twelve months include:

• Market capitalization: USD 4.63 million
• 52-week trading range: USD 0.80 – 2.30
• Earnings per share (TTM): –1.12
• Net loss: USD 4.83 million
• Cash on hand: USD 4.65 million
• Total debt/equity (mrq): 1.56%

The company’s strategy is focused on advancing CMND-100 through early-stage clinical milestones, validating the safety and efficacy profile of MEAI, and positioning the therapy within the growing AUD market. In the U.S., substance abuse treatment was valued at USD 193 billion and alcohol abuse at USD 249 billion, according to Clearmind’s market research. The AUD market alone was estimated at USD 35.1 billion in 2021 and is projected to reach USD 60.2 billion by 2029.

Market Position and Industry Context

Clearmind occupies a niche in the psychedelic medicine sector, aiming to apply compounds with neurochemical activity to address underserved psychiatric conditions. Its focus on MEAI differentiates it from other programs centered on classical psychedelics (e.g., psilocybin or ketamine). With intellectual property protection in place, clinical data from CMND-100 will inform partner discussions and potential regulatory pathways. The company’s valuation reflects the typical risk profiles seen in early-stage biotech, pending proof-of-concept results.

TL;DR

• On June 5, 2025, Clearmind dosed its first patient in the Phase I/IIa CMND-100 trial for Alcohol Use Disorder at Yale School of Medicine.
• SEC filings on June 23, 27, and 30, 2025, report the addition of an Israeli clinical site, a global trial expansion, and the dosing milestone.
• CMND stock closed at USD 1.32 (+46.18%) on July 3, 2025, with 4.58 million shares traded; market cap stands at USD 4.63 million.
• AUD market opportunity is projected to grow from USD 35.1 billion in 2021 to USD 60.2 billion by 2029.
• Upcoming catalysts include safety and preliminary efficacy readouts from the Phase I/IIa study and further clinical site activations.